Payment overview · 2025
General Payments
$1,035.39
39 reported records · 21 companies
Healthcare provider profile · identity verified
John Marshall Strong, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EL CENTRO, CA · NPI 1043248719
Verified facts
What the public records show
CMS Open Payments records show John Marshall Strong, M.D. received $1,035.39 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Shingrix, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.90 | 16.3% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $130.01 | 12.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $122.14 | 11.8% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $88.62 | 8.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.71 | 7.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.02 | 7.0% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $44.80 | 4.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $36.27 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.88 | 3.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.05 | 2.8% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.43 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.18 | 2.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.10 | 2.3% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.97 | 2.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.58 | 2.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.42 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.37 | 1.7% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $17.27 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.16 | 1.7% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.41 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,035.39 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $130.01 | 4 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $104.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $88.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.73 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $36.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
56 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 697 | 322 |
| Omeprazole | Omeprazole | 638 | 262 |
| Losartan Potassium | Losartan Potassium | 596 | 251 |
| Metformin Hcl | Metformin Hcl | 464 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 212 |
| Gabapentin | Gabapentin | 417 | 187 |
| Fluticasone Propionate | Fluticasone Propionate | 373 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 152 |
| Meloxicam | Meloxicam | 339 | 163 |
| Lisinopril | Lisinopril | 330 | 147 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 313 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 112 |
| Tramadol Hcl | Tramadol Hcl | 199 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 94 |
| Ibuprofen | Ibuprofen | 187 | 112 |
| Baclofen | Baclofen | 179 | 109 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 80 |
| Furosemide | Furosemide | 174 | 73 |
| Alendronate Sodium | Alendronate Sodium | 156 | 81 |
| Pioglitazone Hcl | Pioglitazone Hcl | 150 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 59 |
| Ozempic | Semaglutide | 134 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 62 |
| Alprazolam | Alprazolam | 131 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 34 |
| Simvastatin | Simvastatin | 124 | 52 |
| Trazodone Hcl | Trazodone Hcl | 122 | 52 |
| Farxiga | Dapagliflozin Propanediol | 120 | 39 |
| Carvedilol | Carvedilol | 118 | 59 |
| Potassium Chloride | Potassium Chloride | 112 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 28 |
| Sertraline Hcl | Sertraline Hcl | 95 | 44 |
| Trulicity | Dulaglutide | 94 | 26 |
| Sucralfate | Sucralfate | 92 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 23 |
| Famotidine | Famotidine | 87 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 42 |
| Clonidine Hcl | Clonidine Hcl | 85 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 38 |
| Lorazepam | Lorazepam | 84 | 33 |
| Linzess | Linaclotide | 83 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 51 |
| Montelukast Sodium | Montelukast Sodium | 81 | 39 |
| Metformin Hcl Er | Metformin Hcl | 79 | 34 |
| Jardiance | Empagliflozin | 76 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 34 |
| Lidocaine | Lidocaine | 70 | 28 |
| Donepezil Hcl | Donepezil Hcl | 67 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 33 |
| Tradjenta | Linagliptin | 65 | 23 |
| Prednisone | Prednisone | 64 | 51 |
| Clonazepam | Clonazepam | 62 | 26 |
| Eliquis | Apixaban | 62 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Fenofibrate | Fenofibrate | 61 | 28 |
| Glimepiride | Glimepiride | 61 | 33 |
| Aripiprazole | Aripiprazole | 58 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 34 |
| Finasteride | Finasteride | 57 | 25 |
| Celecoxib | Celecoxib | 56 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 56 | 56 |
| Meclizine Hcl | Meclizine Hcl | 55 | 32 |
| Fenofibrate | Fenofibrate,micronized | 50 | 29 |
| Januvia | Sitagliptin Phosphate | 50 | 23 |
| Temazepam | Temazepam | 49 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 17 |
| Cilostazol | Cilostazol | 45 | 12 |
| Pregabalin | Pregabalin | 45 | 23 |
| Ezetimibe | Ezetimibe | 44 | 19 |
| Benazepril Hcl | Benazepril Hcl | 43 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 31 |
| Myrbetriq | Mirabegron | 42 | 18 |
| Tolterodine Tartrate | Tolterodine Tartrate | 42 | 21 |
| Cephalexin | Cephalexin | 41 | 36 |
| Diazepam | Diazepam | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 24 |
| Nifedipine Er | Nifedipine | 40 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 21 |
| Azithromycin | Azithromycin | 36 | 36 |
| Mirtazapine | Mirtazapine | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 17 |
| Entresto | Sacubitril/Valsartan | 34 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Fluconazole | Fluconazole | 32 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Nitroglycerin | Nitroglycerin | 32 | 20 |
| Ondansetron Odt | Ondansetron | 32 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 17 |
| Allopurinol | Allopurinol | 31 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Valsartan | Valsartan | 31 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | 16 |
| Doxepin Hcl | Doxepin Hcl | 29 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | 15 |
| Rybelsus | Semaglutide | 29 | 14 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | 15 |
| Movantik | Naloxegol Oxalate | 27 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | 11 |
| Xarelto | Rivaroxaban | 26 | 12 |
| Naproxen | Naproxen | 25 | 16 |
| Spironolactone | Spironolactone | 25 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | 13 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | 11 |
| Estradiol | Estradiol | 21 | 12 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 17 |
| Gemtesa | Vibegron | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 16 |
| Prolia | Denosumab | 17 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | 11 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,035.39 · 39 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, APTIMA, AREXVY, BEXSERO, CAPVAXIVE, CeQur Simplicity, DAWNZERA, DUPIXENT, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, LEQVIO, NURTEC ODT, Ohtuvayre, PURIFIED CORTROPHIN GEL, QUTENZA, REZDIFFRA, SHINGRIX, TEZSPIRE, TRELEGY ELLIPTA, VALTOCO, Veozah, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error